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Activation of cyclin B-Cdc2 is an absolute requirement
for entry into mitosis, but other protein kinase path-
ways that also have mitotic functions are activated dur-
ing G2/M progression. The MAPK cascade has well estab-
lished roles in entry and exit from mitosis in Xenopus,
but relatively little is known about the regulation and
function of this pathway in mammalian mitosis. Here we
report a detailed analysis of the activity of all compo-
nents of the Ras/Raf/MEK/ERK pathway in HeLa cells
during normal G2/M. The focus of this pathway is the
dramatic activation of an endomembrane-associated
MEK1 without the corresponding activation of the MEK
substrate ERK. This is because of the uncoupling of
MEK1 activation from ERK activation. The mechanism
of this uncoupling involves the cyclin B-Cdc2-dependent
proteolytic cleavage of the N-terminal ERK-binding do-
main of MEK1 and the phosphorylation of Thr286. These
results demonstrate that cyclin B-Cdc2 activity regu-
lates signaling through the MAPK pathway in mitosis.
Growth factors signal cells to proliferate via a complex mech-
anism that links receptor activation to the cell cycle machinery.
Receptor activation induces cells to progress from quiescence
(G0) into G1 phase. Constant receptor stimulation is required
until the restriction point is reached in mid-to-late G1. Once the
restriction point is passed, cell cycle progression is regulated
autonomously by the cell cycle machinery (1). The primary
components of this cell cycle machinery are a family of serine/
threonine kinases, the cyclin-dependent kinases. Cyclin-
dependent kinases are regulated by association with regulatory
cyclin subunits and by phosphorylation (2). Passage through
the eukaryotic cell cycle requires successive activation of dif-
ferent complexes between cyclin and cyclin-dependent kinase
complexes. Progression from G2 to M phase is controlled by
cyclin B-Cdc2.
The MAPK1 cascade, controlled by the small GTPase Ras, is
critical for progression from G1 to S phase (3). Growth factor
receptors recruit Ras guanine nucleotide exchange factors to
the plasma membrane to activate Ras, which then recruits and
activates Raf kinases. In turn, activated Raf phosphorylates
and activates the dual-specificity MAPK kinases (MEK1 and
MEK2) that phosphorylate and activate the MAPKs ERK1 and
ERK2. Activated ERK phosphorylates a wide range of effector
proteins, including transcription factors that increase expres-
sion of proteins required for cell cycle progression into S phase
(3). The MAPK pathway has a clearly defined role in G1 phase
progression, but may also have a role in the G2/M phase of the
cell cycle. In cycling Xenopus egg extracts, addition of activated
MEK during interphase blocks cyclin B-Cdc2 activation by
maintaining Wee1 (4, 5). ERK activity is dispensable for nor-
mal mitotic progression in Xenopus, although ERK activity is
required for the proper functioning of the mitotic spindle (6).
The role of the MAPK pathway in mammalian mitosis is less
clear. The biochemical activities of endogenous ERK1 and
ERK2 have been shown to decrease as cells enter mitosis (7, 8),
yet other studies conclude that activation of the MEK/ERK
cascade is required for normal progression into mitosis (9, 10).
Components of the MAPK pathway have been shown to asso-
ciate with the mitotic apparatus of mammalian cells. Activated
MEK and ERK localize to the mitotic spindle from prophase to
anaphase and to the midbody during cytokinesis (11). Acti-
vated ERK also colocalizes with the kinetochore motor protein
CENP-E, raising the possibility that CENP-E is a downstream
effector for ERK during mitosis (12). Blocking MEK activity in
cycling somatic cells does not significantly affect mitotic entry,
but it does slow progression through mitosis, probably by slow-
ing the CENP-E-dependent chromosome movement coordi-
nated by the mitotic spindle (13).
A number of groups have investigated the regulation of Raf-1
in mitosis using ectopic expression of Raf-1 and nocodazole
treatment to produce a mitotic checkpoint-arrested cell popu-
lation. However, nocodazole treatment itself causes a rapid
activation of Raf-1 independent of mitosis (10), probably due to
disruption of the microtubule network (14). Thus, little is ac-
tually known about the activity of the endogenous Ras/Raf/
MEK/ERK pathway in normal G2/M progression.
In this study, we examined the expression and activation of
all components of the Ras/Raf/MEK/ERK pathway during G2/M
progression. To avoid the use of microtubule-disrupting drugs
like nocodazole that directly influence Raf activity independent
of the cell cycle, HeLa cells were synchronized at G1/S and
allowed to progress through mitosis in the absence of drugs.
Endogenous proteins of the MAPK cascade were then analyzed
biochemically. This approach excludes potentially confounding
results arising from nocodazole treatment and ectopic protein
expression. We show that membrane-bound MEK1 is strongly
activated as cells transit into mitosis, but that this activation is
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uncoupled from ERK, which is inactive in mitosis. The uncou-
pling of MEK activation from ERK is mediated by direct mod-
ifications to MEK1 by the mitotic cell cycle machinery and
requires active cyclin B-Cdc2.
MATERIALS AND METHODS
Reagents and Plasmids—Roscovitine was purchased from BIOMOL
Research Labs Inc. Compound 5 was a kind gift from Professor John
Lazo (University of Pittsburgh). 4,6-Diamidino-2-phenylindole (dihy-
drochloride, hydrate) was purchased from Sigma. Rabbit anti-N-Ras,
anti-K-Ras, anti-H-Ras, anti-B-Raf, anti-MEK1C, anti-MEK1N, anti-
MEK2C, anti-MEK2N, anti-ERK1, and anti-ERK2 polyclonal antibod-
ies were purchased from Santa Cruz Biotechnology Inc. Anti-phospho-
MEK, anti-MEK1/2, and anti-phosphothreonine/proline polyclonal
antibodies and anti-HA, anti-Raf-1, and anti-phospho-ERK antibodies
were purchased from Cell Signaling Technology. Rabbit anti-cyclin B1
and anti-Cdc2 polyclonal antibodies were as previously described (15).
Mouse anti--tubulin monoclonal antibody was purchased from Amer-
sham Biosciences. Horseradish peroxidase-conjugated anti-rabbit and
anti-mouse and fluorescein isothiocyanate-conjugated anti-mouse goat
polyclonal antibodies were purchased from Zymed Laboratories Inc.
Plasmid pLNCAL-HA-tagged wild-type MEK1, MEK1(S218D/S222D),
MEK132–51, and MEK1(T286A) were a generous gift from Dr. Andy
Catling (16). GFP- and HA-tagged MEK1N51 was produced by PCR of
the open reading frame of wild-type MEK1 or MEK1(S218D/S222D)
from residue 51 to the termination codon, such that it was cloned
in-frame into the pEGFP vector (Clontech).
Cell Lines and Culture Conditions—HeLa and 293H (Invitrogen)
cells were grown in Dulbecco’s modified Eagle’s medium supplemented
with 10% bovine donor serum (Serum Supreme, BioWhittaker, Inc.).
Assays for Mycoplasma were carried out monthly to ensure that the
cultured cells were free of contamination. HeLa cells were synchronized
using a double thymidine block release protocol as described (17). Mi-
totic shake-off was used to obtain a highly enriched mitotic cell popu-
lation from double thymidine-synchronized cells passing through mito-
sis. 293H cells were transfected using LipofectAMINE 2000
(Invitrogen) as directed by the manufacturer. HeLa cells were trans-
fected by electroporation. Cell cycle status of cultures was assessed by
flow cytometry as described previously (17).
Cell Fractionation and Immunoblotting—Floating and attached cells
were harvested in ice-cold PBS and pelleted by low speed centrifugation
(1000 rpm) at 4 °C. PBS was removed, and cell pellets were resus-
pended in 0.5 ml of buffer A (10 mM Tris-HCl (pH 7.5), 25 mM NaF, 5 mM
MgCl2, 1 mM EGTA, 1 mM dithiothreitol, and 100 M NaVO4) and
homogenized by passage through a 23-gauge needle. The post-nuclear
supernatants were spun at 100,000  g; the supernatants (S100) were
removed; and the sedimented fractions (P100) were rinsed and soni-
cated for 5 min in 100 l of ice-cold buffer A. Protein content was
measured by the Bradford reaction. P100 and S100 aliquots were snap-
frozen and stored at 70 °C. Protein expression levels were determined
by quantitative immunoblotting. 20 g of P100 and an equivalent
volume of S100 were resolved on SDS-polyacrylamide gels and trans-
ferred to polyvinylidene difluoride membranes by semidry transfer.
Proteins were detected using the appropriate primary antibodies fol-
lowed by horseradish peroxidase-conjugated anti-mouse or anti-rabbit
secondary antibody. Bands were visualized by enhanced chemilumines-
cence (ECL), and relative luminescence was quantified by phosphorim-
aging (Bio-Rad). Levels of Ras-GTP were assayed using bacterially
expressed GST-Raf-RBD(K85A) to bind Ras-GTP, which was detected
by immunoblotting with Ras isoform-specific antibodies (18).
Two-dimensional Gel Electrophoresis—Membrane-bound MEK1 was
solubilized for two-dimensional analysis by addition of 100 l of 0.5%
SDS in PBS to a 1% Nonidet P-40 membrane pellet (from a 10-cm dish
of mitotic HeLa cells) and incubation at 37 °C for 10 min with vigorous
shaking and then addition of 150 l of 5% Nonidet P-40 and sonication
for 10 min at 4 °C in a sonicating water bath. The solubilized protein
was acetone-precipitated and resuspended in 250 l of rehydration
buffer (5 M urea, 2 M thiourea, 2% CHAPS, 2% SB310, 4 mM Tris-Cl (pH
9.5), and bromphenol blue to color) with freshly added dithiothreitol
and pH 3–10 carrier ampholytes (two-dimensional) to final concentra-
tions of 50 mM and 1%, respectively. The first dimension was resolved
on a pH 3–10 linear ImmobilineTM DryStrip (Amersham Biosciences)
for 100 kV-h after 18 h of rehydration. The second dimension was
resolved on 12% SDS-polyacrylamide gel. Western transfer and immu-
noblotting were performed as described above.
Kinase Assays—Raf kinase assays were performed essentially as
described (19). Briefly, equivalent P100 aliquots (20 g of total protein)
were incubated in kinase buffer (buffer A containing 0.5 mM ATP and 5
mM MgCl2) at 30 °C for 30 min with recombinant MEK and ERK (tube
A; to measure total Raf, MEK, ERK, and nonspecific kinase activities),
ERK alone (tube B; to measure MEK, ERK, and nonspecific kinase
activities), or buffer alone (tube C; to measure ERK and nonspecific
kinase activities). Primary reactions were diluted in buffer A, and an
aliquot was incubated in a second reaction containing [-32P]ATP and
myelin basic protein. The radioactivity incorporated into myelin basic
protein was quantified by phosphorimaging. Total P100 Raf kinase
activity was the difference in the activities in tubes A and B, as P100-
associated Raf-1 and B-Raf are insoluble in 1% Nonidet P-40 (19). Total
P100 MEK activity was the difference in activities in tubes B and C.
MEK-specific activity was estimated by dividing the total P100 MEK
kinase activity by the amount of P100 phospho-MEK present (deter-
mined by quantitative Western analysis as described above).
To measure cytosolic Raf activity, volumes of the S100 fraction pro-
portional to the P100 aliquots assayed above were diluted into 1 ml
(final volume) of buffer B (50 mM Tris-HCl (pH 7.5), 75 mM NaCl, 5 mM
MgCl2, 25 mM NaF, 5 mM EGTA, 100 M NaVO4, 1% Nonidet P-40, 1 mM
dithiothreitol, 5 g/ml aprotinin, 5 g/ml leupeptin, and 5 g/ml pep-
statin A). Samples were rotated for 3 h at 4 °C either with 2 g of
anti-Raf-1 antibody plus 10 l of protein G beads or with 2 g of
anti-B-Raf antibody plus 10 l of protein A beads. The beads were
washed three times with buffer B and three times with buffer A and
then resuspended in kinase buffer for assaying. Kinase assays were
performed on the washed beads using the coupled MEK/ERK assay as
described above. To ensure comparable results, P100 and S100 fractions
were assayed at the same time using the same reaction buffers and then
quantified simultaneously by phosphorimaging. As the P100 and S100
fractions analyzed were equivalent, total measurable Raf kinase activ-
ity was determined by adding total P100, S100 Raf-1, and S100 B-Raf
kinase activities together. This value is referred to as total Raf kinase
activity. Cyclin B1 kinase assays were performed as described (17).
Immunofluorescent Staining—For immunostaining, cells were
grown on poly-L-lysine-coated coverslips. Coverslips were washed with
PBS, and then the cells fixed with 3% paraformaldehyde or ice-cold
methanol and stored at 20 °C until required. Coverslips were washed
three times with PBS and then blocked in blocking buffer (PBS con-
taining 0.1% Tween 20 and 3% bovine serum albumin) for 1 h at room
temperature. The cells were stained with anti--tubulin antibody (1:
1000 dilution in blocking buffer), washed five times for 5 min, stained
with Texas Red-conjugated anti-mouse antibody (1:300 dilution in
blocking buffer containing 10 g/ml 4,6-diamidino-2-phenylindole for
DNA counterstaining) for 30 min, washed five times with PBS, and
mounted on slides. Photomicroscopy was performed as described previ-
ously (17).
RESULTS
Analysis of the Ras/Raf/MEK/ERK Pathway during the Cell
Cycle—To examine the expression and activity of the compo-
nents of the Ras/Raf/MEK/ERK pathway during cell cycle pro-
gression, we synchronized HeLa cell cultures with a double
thymidine block. Using this protocol, 80% of the cells pro-
gressed synchronously through the S, G2, and M phases and
into the subsequent G1 phase. By 6 h after release from the
thymidine block, 85% of the cells progressed to G2 phase and,
after 9 h, entered mitosis (Fig. 1A). Entry and exit from mitosis
were determined by measuring cyclin B1-Cdc2 kinase activity.
Cyclin B1-Cdc2 activity increased at 8 h after release from the
thymidine block, peaked at 9–10 h, and returned to basal levels
by 12 h (Fig. 1B).
These synchronized cells were used for a detailed biochemi-
cal analysis of the expression levels and activities of the endog-
enous components of the Ras/Raf/MEK/ERK pathway through-
out the cell cycle. In HeLa cells, K-Ras and N-Ras were strongly
expressed at constant levels throughout the cell cycle (Fig. 1G).
H-Ras was also expressed, but at very low levels (data not
shown). Ras-GTP loading was measured in a sensitive GST-
Raf-RBD binding assay that permits GTP loading of each Ras
isoform to be assessed simultaneously (18). N-Ras displayed
two peaks of GTP loading. The first, smaller peak occurred 12 h
after release from the thymidine block and correlated with exit
from mitosis. The major peak of N-Ras-GTP loading occurred in
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late G1 phase (18 h), consistent with a role in G1/S transition
(Fig. 1, C and G). In contrast, K-Ras-GTP levels remained
uniformly low throughout the cell cycle, and H-Ras-GTP load-
ing was undetectable (data not shown).
Membrane-associated and cytosolic pools of Raf, MEK, and
ERK have different specific activities (19) and possibly access
to different substrates. We therefore measured the activities of
Raf, MEK, and ERK in membrane (P100) and cytosolic (S100)
fractions. The activities of B-Raf and Raf-1 were measured in a
coupled MEK/ERK kinase assay (19). Total P100-associated
Raf kinase activity and S100-associated B-Raf and Raf-1 ki-
nase activities were assayed. The P100 Raf kinase activity
profile had two peaks (Fig. 1, D and H). The first peak occurred
8–9 h after release from the thymidine block in late G2/early
mitosis. Interestingly, this early peak of Raf kinase activity did
not correlate with the small peak of Ras-GTP loading that
FIG. 1. Analysis of the MAPK pathway during the cell cycle. HeLa cells were synchronized by double thymidine block/release, and the
MAPK pathway was analyzed as cells progressed through mitosis into the subsequent G1 phase. This experiment was repeated three times with
similar results. A, fluorescence-activated cell sorter analysis of the DNA content of cells harvested after release. The percentage of cells in G1 (f),
S (), and G2/M (E) for each time point is shown. Entry into G2 phase occurred 6 h after release, and entry into mitosis occurred 9–10 h after
release. B, cyclin B1-Cdc2 kinase activity assayed as a marker for mitosis. Peak mitosis is indicated by the dashed line. C, Ras-GTP loading (only
N-Ras is shown). D, total Raf kinase activity. E, level of pMEK in the P100 (f) and S100 () fractions. F, level of pERK in the P100 (f) and S100
() fractions. G–J, the levels and activities of Ras (G), B-Raf and c-Raf-1 (H), MEK1 and MEK2 (I), and ERK1 and ERK2 (J).
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occurred in late mitosis (Fig. 1, C and D). The second peak of
P100 Raf kinase activity occurred in G1 phase (14–18 h) and
correlated with the major peak of N-Ras-GTP loading (Fig. 1, C
and D). Cytosolic B-Raf activity essentially mirrored P100-
associated Raf activity, whereas cytosolic Raf-1 was not acti-
vated during mitosis, but was activated in G1 (Fig. 1H). The
levels of P100 Raf-1 and B-Raf proteins were constant through-
out S and G2 (up to 8 h), fell during mitosis (at 9–12 h), and
then increased again during G1 (at 15–18 h). The levels of
cytosolic Raf-1 and B-Raf were constant (Fig. 1H).
MEK activation was assayed with phospho-specific antisera
that recognize activated MEK1 and MEK2 (pMEK). Two peaks
of pMEK were observed. The first peak occurred in late G2/
early mitosis and was entirely confined to the P100 membrane
fraction (Fig. 1, E and I). The second, smaller peak occurred in
G1 phase (14–18 h), but was entirely confined to the S100
fraction. Both peaks of MEK activation corresponded with
peaks of Raf activity (Fig. 1, D and E). The levels of membrane-
associated MEK1 and, to a lesser extent, MEK2 decreased
during mitosis (10–12 h), but cytosolic MEK levels remained
constant (Fig. 1I). The activation of ERK was assayed in the
same fractions using activation- and phospho-specific antisera
(pERK). The level of pERK dramatically decreased in both
P100 and S100 fractions during mitosis, but rapidly recovered
during G1 progression (Fig. 1, F and J). The levels of ERK1 and
ERK2 did not change throughout the cell cycle (Fig. 1J).
Immunofluorescent staining for pMEK revealed strong
staining of mitotic cells (Fig. 2). This mitotic pMEK staining
pattern was observed in both asynchronously growing and syn-
chronized cultures, thus was not an artifact of the synchrony
protocol. The staining was dispersed throughout the cells, al-
though weak accumulation at the spindle poles was observed in
some cells (data not shown), as reported previously (11). Inter-
phase cells had low levels of phospho-MEK staining. Therefore,
these results support the results from pMEK immunoblot anal-
ysis (Fig. 1, E and I).
Cyclin B-Cdc2 Activity Is Required to Uncouple Mitotic MEK
and ERK Activation—The very high level of membrane-bound
pMEK in mitotic cells surprisingly correlated with a loss of
active ERK, whereas by contrast, ERK was strongly activated
in G1 in response to the more modest peak of MEK activity (Fig.
1, E and F). This observation strongly suggested that the cou-
pling between MEK and ERK activation was lost in mitosis. To
establish whether this loss of coupling was a direct conse-
quence of entry into mitosis, synchronized HeLa cells were
arrested in late G2 phase by treatment with Compound 5, an
inhibitor of the Cdc2 activator Cdc25 (20), or with roscovitine,
a direct inhibitor of Cdc2 (21). Membrane fractions of these
G2-arrested cells were compared with untreated mitotic shake-
off HeLa populations by immunoblotting for pMEK and pERK
using ERK2 as a protein input control. Both Cdc2 inhibitor-
treated samples had reduced pMEK levels relative to normal
mitotic cells, but pERK levels in the drug-treated cells were
substantially higher than those in normal mitotic cells, which
had barely detectable levels of pERK (Fig. 3A). This result
suggests that a mitotic factor either blocks access of activated
MEK to ERK or directly modifies activated MEK so that it is
unable to activate ERK. To differentiate between these possi-
bilities, the activity of membrane-associated MEK was assayed
in an in vitro coupled ERK1 kinase assay. Membrane-associ-
ated pMEK from roscovitine-treated G2-arrested cells had a
10-fold higher specific activity than pMEK from control mitotic
cell populations (Fig. 3B). These results strongly suggest that
activated MEK is directly modified as cells enter mitosis to
inhibit its ability to activate ERK.
MEK1 (but Not MEK2) Is Cleaved and Activated during
Mitosis—Earlier studies that examined MEK activity in mito-
sis (10, 22) did not detect the dramatic MEK activation shown
in Fig. 1I, but these studies analyzed only detergent lysates of
mitotic cells. We therefore tested the detergent solubility of
P100-associated pMEK. P100 fractions prepared from mitotic
HeLa cells were solubilized in 1% Nonidet P-40, and the soluble
and insoluble fractions were immunoblotted for pMEK, MEK1,
and MEK2. pMEK was insoluble in 1% Nonidet P-40, whereas
MEK1 was highly soluble, and MEK2 had low solubility
(Fig. 4A).
To determine which MEK isoform was activated during mi-
FIG. 2. MEK is activated in mitosis. HeLa cells were fixed in 3%
paraformaldehyde and immunostained for pMEK, and DNA was
stained with 4,6-diamidino-2-phenylindole. Mitotic cells (Mt) were iden-
tified and photographed using confocal microscopy. Shown are mitotic
cells displaying typical strong pMEK staining. The surrounding inter-
phase cells displayed little staining. A similar pattern was observed
with methanol fixation.
FIG. 3. Cyclin B-Cdc2 activity uncouples MEK phosphoryla-
tion from ERK activation during mitosis. A, synchronized HeLa
cells were treated with 20 M Compound 5 or 50 M roscovitine 7 h after
release and harvested at 10 h, when controls were at peak mitosis. Cells
were fractionated, and the P100 membrane fractions were then immu-
noblotted for pMEK and pERK. ERK2 was used as an input control. B,
synchronized HeLa cells were treated with roscovitine as described for
A; equivalent untreated mitotic HeLa cells were fractionated; and the
P100 membrane fraction was assayed for MEK kinase activity. Identi-
cal membrane fractions were immunoblotted for pMEK. MEK-specific
activity was calculated as described under “Materials and Methods.”
ERK2 was immunoblotted as an input control.
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tosis, the Nonidet P-40-insoluble P100 fraction of mitotic HeLa
cells was electrophoresed on high resolving SDS-polyacryl-
amide gel and then immunoblotted for pMEK with antibodies
raised against the N and C termini of MEK1 (anti-MEK1N and
anti-MEK1C antibodies) and MEK2 (anti-MEK2N and anti-
MEK2C antibodies). The phosphorylated form of MEK mi-
grated with an apparent molecular mass of 37 kDa. Anti-
MEK1C antibody detected three bands, a 44-kDa band
corresponding to unmodified MEK1 and cytosolic pMEK and
two more rapidly migrating bands, the most abundant of which
comigrated with the 37-kDa band detected by anti-pMEK an-
tibody (Fig. 4B). Anti-MEK1N, anti-MEK2N, and anti-MEK2C
antibodies did not detect a 37-kDa band. To confirm that the
37-kDa band detected by anti-pMEK antibody was indeed
MEK1, the mitotic P100 fraction was resolved by two-dimen-
sional isoelectric focusing/SDS-PAGE and then immunoblotted
for pMEK and for MEK1 and MEK2 with an antibody that
detects both MEK isoforms (anti-MEK1/2 antibody). pMEK
exactly comigrated with the minor species detected by anti-
MEK1/2 antibody, confirming the identity of the species as a
truncated form of pMEK1 (Fig. 4C).
MEK1 Cleavage Is Dependent on Cyclin B-Cdc2 Activity—To
determine the timing of MEK1 cleavage, the Nonidet P-40-
insoluble P100 fraction from the experiment shown in Fig. 1I
was run on high resolving SDS-polyacrylamide gel and immu-
noblotted with anti-MEK1C antibody. Full-length 44-kDa
MEK1 was the major species in S and G2, but 37-kDa MEK1
increased in late G2 to become the major form in mitosis (Fig.
5A). As cells exited mitosis and entered G1, the shorter form
was lost, and the full-length 44-kDa form of MEK1 reappeared.
This suggested that MEK1 was cleaved during mitosis and that
the cleaved protein was stable only during mitosis. To confirm
that MEK1 cleavage was a mitosis-specific event, synchronized
HeLa cells were allowed to progress into mitosis or were ar-
rested in G2 by addition of the Cdc2 inhibitor roscovitine. P100
fractions from these cells were then immunoblotted with anti-
pMEK, anti-MEK1C, and anti-MEK1N antibodies. Blocking
cyclin B-Cdc2 activity and entry into mitosis reduced MEK
activation and MEK1 cleavage (Fig. 5B), confirming that
MEK1 cleavage is a mitosis-specific event that is dependent on
cyclin B-Cdc2 kinase activity.
Mitosis-specific Cleavage of the N-terminal ERK-binding Do-
main of MEK1—The detection of mitotic pMEK1 with only
anti-MEK1C and anti-MEK1/2 antibodies suggested that the
faster migrating species was the result of proteolytic cleavage
of the N-terminal region of MEK1. The apparent size difference
FIG. 4. MEK1 (but not MEK2) is cleaved and activated in mi-
tosis. A, mitotic HeLa cells prepared from synchronized cultures by
mechanical shake-off were fractionated, and the membrane fraction
was solubilized in buffer A with or without 1% Nonidet P-40 (NP40).
Insoluble (I) and soluble (S) fractions were run in triplicate on SDS-
polyacrylamide gel and probed for pMEK, MEK1, and MEK2. B, the
Nonidet P-40-insoluble fraction from mitotic HeLa cells was run on high
resolving SDS-polyacrylamide gel and transferred to a membrane. The
membrane was cut into strips and probed for pMEK, MEK1 with an N
terminus-specific antibody (anti-MEK1N) and a C terminus-specific
antibody (anti-MEK1C), and MEK2 with an N terminus-specific anti-
body (anti-MEK2N) and a C terminus-specific antibody (anti-MEK2C).
The strips were carefully realigned upon development so that mobility
shifts between the isoforms could be observed. C, the Nonidet P-40-
insoluble fraction from a 10-cm dish of HeLa cells arrested in mitosis
was resolved by two-dimensional gel electrophoresis and transferred to
a membrane. The membrane was marked with three orientation spots
and then probed for pMEK, stripped, and reprobed for MEK1 and
MEK2 with anti-pan MEK1/2 antibody. Two exposures (exp) of the
MEK1/2 blot are shown. The arrow indicates the minor form of MEK
detected by anti-MEK1/2 antibody, which overlaid the strong pMEK
spot.
FIG. 5. MEK1 cleavage is dependent on cyclin B-Cdc2 activity.
A, samples from the experiment shown in Fig. 1 were assayed for cyclin
B1-Cdc2 activity as a marker for mitosis. The Nonidet P-40-insoluble
P100 fraction was immunoblotted with anti-MEK1C antibody to indi-
cate the time point at which MEK1 cleavage occurred. B, synchronized
HeLa cells were allowed to progress into mitosis or arrested at G2 by
addition of 50 M roscovitine added 7 h after release. The Nonidet
P-40-insoluble membrane fractions were run on high resolving SDS-
polyacrylamide gel and immunoblotted with anti-pMEK, anti-MEK1N,
and anti-MEK1C antibodies. A G1/S cell population at time 0 is included
for comparison.
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between full-length 44-kDa MEK1 and mitotic pMEK1 was 5–7
kDa, indicating that the cleavage occurred in the region of
residues 40–60. This was investigated using a MEK1 internal
deletion mutant with residues 32–51 removed (MEK132–51).
HeLa cells were transfected with HA-tagged versions of wild-
type MEK1 and MEK132–51 and either untreated or arrested
in mitosis with nocodazole, which produced essentially identi-
cal accumulation of the faster migrating pMEK species ob-
served in normal mitotic samples. S100 and P100 fractions
were prepared and immunoblotted for the HA-tagged proteins.
The level of HA-tagged wild-type MEK1 in the P100 fraction
from mitotic cells was reduced compared with the untreated
asynchronously growing culture (Fig. 6A). This paralleled the
reduction in MEK1 detected with anti-MEK1N antibody in
normal mitotic P100 fractions (Fig. 5B). There was little change
in the level of HA-tagged MEK132–51 in the P100 fractions
from asynchronous and nocodazole-arrested mitotic cells (Fig.
6A). The levels of these proteins were constant in the S100
fractions from asynchronous and mitotic cells.
The insensitivity of the MEK132–51 constructs to N-termi-
nal cleavage suggested either that the deleted residues 32–51
contain the proteolytic cleavage site or that the tertiary struc-
ture of the deleted protein masks the cleavage site. To discrim-
inate between these possibilities, the N-terminal 51 residues of
MEK1 were replaced with either an HA tag (HA-MEK1N51)
or GFP (GFP-MEK1N51). Immunoblotting of the P100 frac-
tion prepared from mitotic cells expressing GFP-MEK1N51
revealed the presence of the full-length chimera, detected by
both anti-MEK1C and anti-GFP antibodies, and an abundant
37-kDa MEK1 protein, detected only by anti-MEK1C antibody
and corresponding to MEK1N51 cleaved of the GFP moiety.
This band comigrated with 37-kDa pMEK (Fig. 6B). The full-
length chimera was the major form of the protein detected in
the corresponding S100 fractions (Fig. 6B). Immunoblotting of
HA-MEK1N51 with anti-HA antibody revealed a similar loss
of HA tag in the P100 fraction (data not shown).
The N terminus of MEK1 contains the ERK-binding domain
(23). The removal of this region could explain the uncoupling of
MEK1 activation from ERK activation in mitosis. To test this
hypothesis, the level of endogenous ERK activation was exam-
ined in the P100 and S100 fractions from mitotic cultures
overexpressing a constitutively activated form of MEK1
(HA-MEK1(S218D/S222D)) or GFP-MEK1N51(S218D/
S222D). The N-terminal deletion mutant failed to activate ERK
in the S100 fraction compared with constitutively activated
full-length MEK1, but the GFP-MEK1N51(S218D/S222D)
mutant activated ERK in the P100 fraction of asynchronously
growing cells (Fig. 6C). Interestingly, GFP-MEK1N51(S218D/
S222D) failed to activate ERK in the P100 fraction of mitotic
cells, although ERK activation by MEK1(S218D/S222D) was
unaffected (Fig. 6C).
Phosphorylation of MEK1 Thr286 Uncouples MEK1 Activity
from ERK Activation—The preceding experiments suggested
that cleavage of the N-terminal ERK-binding domain was not
sufficient to fully uncouple mitotic P100 MEK1 activation from
ERK phosphorylation in vivo, except in mitotic cells. MEK1
contains consensus sequences for phosphorylation by cyclin
B-Cdc2 at Thr286 and Thr292, and both of these residues are
phosphorylated by cyclin B-Cdc2 in vitro, resulting in down-
regulation of MEK1 activity (24). However, phosphorylation of
Thr292 does not appear to affect MEK1 activity (16); therefore,
we examined the phosphorylation of Thr286 in mitosis and its
role in regulating mitotic MEK1 activity by substituting Thr286
with Ala in HA-tagged wild-type MEK1 (HA-MEK1(T286A)).
Cells transfected with empty vector, MEK1, or MEK1(T286A)
were arrested in mitosis by 18 h of nocodazole treatment and
then fractionated for analysis. Ectopic expression of MEK1 or
MEK1(T286A) did not affect mitotic MEK1 activation, as
pMEK levels remained constant in all transfected cell popula-
tions. Immunoblotting of the S100 and P100 fractions with
antibody specific for phosphothreonine/proline consensus sites
for cyclin B-Cdc2-dependent phosphorylation revealed a strong
band corresponding to ectopic MEK1, which was greatly re-
duced with mutation of Thr286 (Fig. 7). Examination of the level
of ERK activation in these transfected cultures showed that the
T286A substitution was sufficient to allow robust ERK activa-
tion during mitosis in both the membrane and cytosolic frac-
FIG. 6. The N-terminal ERK-binding domain of MEK1 is pro-
teolytically cleaved in mitosis. A, 293H cells were transfected with
empty vector or HA-tagged MEK1 constructs and harvested as asyn-
chronous (without nocodazole) or mitotic (with 0.5 g/ml nocodazole for
18 h) populations. Cells were fractionated into S100 and Nonidet P-40-
insoluble P100 fractions, normalized for protein content, and then im-
munoblotted for the HA epitope. B, HeLa cells were transfected with
either GFP or GFP-MEK1N51; then after 8 h, the cells were treated
with nocodazole for 18 h to arrest them in mitosis. Cells were fraction-
ated as described for A and immunoblotted with the indicated antibod-
ies. C, HeLa cells were transfected with empty vector (mock), HA-
MEK1(S218D/S222D) (DD), or GFP-MEK1N51(S218D/S222D). The
cultures were either untreated or arrested in mitosis with nocodazole.
The cells were fractionated and immunoblotted with the indicated
antibodies.
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tions. We conclude that MEK1 phosphorylation by cyclin B-
Cdc2 at Thr286 is necessary to uncouple MEK and ERK
activation during mitosis.
DISCUSSION
There has been evidence from a number of eukaryotic models
that components of the Ras/Raf/MEK/ERK signaling pathway
are involved in mitosis, but their precise role and regulation
have remained elusive. In this work, we present a comprehen-
sive study of the activity of individual components of the Ras/
Raf/MEK/ERK pathway throughout the cell cycle.
Our study has provided some insights into the role of Ras in
cell cycle progression. We found that, in HeLa cells, N-Ras and
K-Ras were both strongly expressed, but only N-Ras was sig-
nificantly activated during the cell cycle. It is currently unclear
why K-Ras was not activated, although Ras isoforms do have
different biological functions in vivo (25). The Ras isoforms
vary in their ability to activate downstream effectors such as
Raf and phosphatidylinositol 3-kinase (26) and in their sensi-
tivity to activation by specific guanine nucleotide exchange
factors (18). N-Ras has also been shown to have a role in
suppressing apoptosis (27), and it is possible that the selective
activation of N-Ras during normal cell cycle progression is
related in some way to an anti-apoptotic role. The small peak of
N-Ras activation in late mitosis/early G1 that was not corre-
lated with Raf activation could be especially relevant in this
context. Alternatively, this N-Ras activity may be involved in
activation of the Rho family GTPases that function in exit from
mitosis and cytokinesis. In contrast, N-Ras-GTP loading in G1
appears to be directly linked with activation of Raf, MEK, and
ERK. The peak of mitotic Raf activation did not correlate with
an increase Ras activation; nevertheless, some activated N-
Ras-GTP was present when Raf was active. Thus, Raf activa-
tion during normal mitosis may be Ras-dependent, but other
factors or activation mechanisms specific to mitosis probably
augment Raf activity in an as yet undefined manner. This may
account for the Ras-independent mitotic Raf activity reported
by others (10, 28). The mitotic peak of Raf activity correlates
well with mitotic MEK1 activation, suggesting that Raf acti-
vates MEK1 during G2/M progression.
The major finding of this study is the dramatic activation of
MEK1 during mitosis and the uncoupling of this activation
from the activation of its substrate ERK. Other groups have
reported MEK activation in G2/M (10, 11, 13, 22), but the
extent of activation has been overlooked, probably due to mi-
totically activated MEK1 being restricted to a detergent-insol-
uble membrane fraction. Although MEK1 is strongly activated
in mitosis, we observed very little concomitant ERK activation,
in agreement with previous studies (8, 10, 13). This uncoupling
of MEK from ERK activation in mitosis is particularly appar-
ent when compared with the strong ERK activation in the
subsequent G1 phase, which correlates with a much more mod-
est level of MEK activation. Thus, it appears that the focus of
the MAPK pathway in mitosis is the activation of MEK1, in
contrast to its G1 role of activating ERK. The observation that
there is considerably more active MEK present during G2/M
progression than during any other stage of the cell cycle poses
several intriguing questions concerning MEK activation during
mitosis. How is MEK1 specifically activated during mitosis?
How is such a robust activation of MEK so efficiently uncoupled
from its downstream effector ERK? And finally, what function
does MEK have in somatic cell G2/M progression?
Mitotic MEK1 activation and its uncoupling from ERK acti-
vation are dependent on cyclin B-Cdc2 activity. A number of
mechanisms contribute to this uncoupling. We have shown that
MEK1 is cleaved during mitosis, removing a 5–7-kDa N-termi-
nal segment of the protein, and this is dependent on cyclin
B-Cdc2 activity. The mitotic proteolytic cleavage site in MEK1
appears to be located after residue 51 because GFP-
MEK1N51 remained sensitive to mitotic cleavage. The MEK1
N-terminal region contains an ERK-binding domain, and dele-
tion or proteolytic removal of this domain by anthrax toxin
lethal factor or caspases renders MEK1 incapable of activating
ERK (29, 30). Here we show that, in asynchronous cell popu-
lations, the loss of the ERK-binding domain is sufficient to
completely inhibit cytosolic ERK activation, but that the ERK-
binding domain is not required for MEK1N51 to activate
membrane-bound ERK. One possible mechanism that may ac-
count for this is the presence of scaffold proteins such as MP-1
that can bind both MEK and ERK and thereby compensate for
the loss of the ERK-binding domain from MEK1N51 (31).
Nevertheless, the ability of truncated MEK1N51 to activate
membrane-bound ERK is lost in mitosis, demonstrating that
additional mitosis-specific mechanisms exist to inhibit MEK
activity for ERK.
Cyclin B-Cdc2 can phosphorylate MEK1 at Thr286 and
Thr292 in vitro, and this phosphorylation reduces MEK1 activ-
ity for ERK (24). We have demonstrated that phosphorylation
of Thr286 occurs in vivo in mitosis and is necessary to uncouple
active MEK1 from ERK during mitosis. Mutation of Thr286 did
not affect the mitosis-specific N-terminal cleavage of MEK1,
suggesting that the cyclin B-Cdc2 dependence of this event is
not through the direct modification of MEK1, but is an indirect
consequence of its activity.
The mitotic activation of MEK1 during mitosis suggests a
novel function for this MEK isoform during mitotic progression.
MEK1 and MEK2 are highly homologous, although their se-
quences are divergent in the N-terminal 30–40 residues and
FIG. 7. Mitotic phosphorylation of MEK1 Thr286 uncouples
MEK and ERK activation. HeLa cell were transfected with either
empty vector or the indicated HA-tagged MEK1 constructs and then
arrested in mitosis with nocodazole. Cells were fractionated and immu-
noblotted with anti-phosphothreonine/proline antibody (p-TP), anti-HA
tag antibody, or anti-endogenous pMEK, pERK, or ERK2 antibody. The
anti-phosphothreonine/proline band in the wild-type (wt) MEK1-ex-
pressing cells was confirmed as transfected HA-MEK1 by immunopre-
cipitation of the HA-tagged protein and anti-phosphothreonine/proline
immunoblotting (data not shown).
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the Thr286/Thr292 phosphorylation sites, which are not con-
served in MEK2 (24). The almost complete sequence identity in
the region of the putative mitotic cleavage site makes it diffi-
cult to propose a model for the isoform-specific cleavage and
activation of MEK1 during mitosis, although tertiary struc-
tural considerations involving the nonconserved N-terminal
regions may be involved. We have provided evidence that Raf is
active in G2/M; however, the mechanism specifically targeting
MEK1 for activation or alternately blocking MEK2 activation
requires further investigation.
The down-regulation of ERK activation by two distinct mech-
anisms may be essential in facilitating proper G2/M progres-
sion, as ERK is able to up-regulate the cyclin B-Cdc2 inhibitor
Wee1 kinase and thereby delay entry into mitosis (4, 5). It is
also tempting to speculate that membrane-associated mitoti-
cally activated MEK1 may have substrates other than ERK
during mitosis. In this context, it has been suggested that the
MEK contribution to Golgi fragmentation in mitosis involves
MEK phosphorylation of non-ERK substrates (22). However,
immunofluorescent staining performed during this study
showed that pMEK was widely dispersed in mitosis, and co-
staining with a Golgi marker revealed that the majority of
mitotically activated MEK1 was not Golgi-associated.2 Further
ultrastructural and fractionation studies will be required to
definitively localize mitotically activated MEK1 as a first step
in unraveling the mechanisms involved in the isoform-specific
activation and cleavage of MEK1 as well as identifying poten-
tial novel MEK substrates.
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